Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965036 · ClinicalTrials.gov registry record
Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior and Posterior Circulation
A clinical trial of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion, sponsored by Azienda Unità Sanitaria Locale della Romagna.
- Active
- Registry status
- 2,880
- Enrollment target
- 3
- Study locations
NCT06965036: Active study of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion, sponsored by Azienda Unità Sanitaria Locale della Romagna.
NCT06965036 is a study of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion that is active but no longer recruiting, run by Azienda Unità Sanitaria Locale della Romagna. The registered enrollment target is 2,880 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06965036, a study of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion, is active but no longer recruiting, sponsored by Azienda Unità Sanitaria Locale della Romagna.
- ACTIVE NOT RECRUITING
- Registry status
- 2,880 participants
- Enrollment target
- 3
- Study locations
Study Summary
CERES-TANDEM is a multicenter study designed to improve the understanding of "tandem" ischemic stroke -those caused by two blockages in series, one in a neck artery and one in a brain artery-. Because tandem occlusion-related stroke tend to cause more severe brain injury and have been under-represented in major clinical trials, there is no clear consensus on which treatments work best. This study will help identify who is most at risk and which therapies lead to the best recovery. OBJECTIVES: Identify Risk Factors: Compare common stroke risk factors (e.g., high blood pressure, diabetes, high cholesterol, smoking) in patients with tandem occlusion versus those with single-site large vessel occlusions. Compare Clinical Outcomes of Reperfusion: Evaluate whether acute reperfusion treatments-such as clot-dissolving drugs (thrombolysis), mechanical clot removal (thrombectomy), and emergent carotid stenting-lead to better 3-month functional outcome (assessed by the modified Rankin Scale, ranging 0 to 6, with good functional outcome identified with mRS score 0-2) compared to medical management alone in tandem occlusion and isolated cervical artery occlusion. Assess Post Stent Therapy: Among patients who receive emergent stenting, determine whether different post-stenting regimens (antiplatelet agents, anticoagulants, or no additional therapy) affect functional outcomes, bleeding events, or stroke recurrence. STUDY DESIGN: Type: cohort study pooling data from prospective registries of cerebrovascular diseases at participating sites Setting: Stroke Unit, Cesena Hospital (PI MR), Interventional Neuroradiology, Vall d'Hebron Research Institute, Barcelona (PI FD), Radiology, Boston Medical Center (PI TN); and other participating stroke centers Time Frame: Patients treated between 2018 and 2024. Sample Size: Approximately 2800 cases overall DATA COLLECTION: Sources: Clinical records, imaging reports (CT perfusion, angiograms), lab results, hospital discharge summaries, an
Primary Outcome
modified Rankin Scale ranges 0 to 6, with 0 being optimal outcome (full autonomy) and 6 being mortality.
Conditions Studied
Study Locations (3)
Other
- Bufalini Hospital Comprehensive Stroke Center - Cesena
- Vall d'Hebron Institut de Recerca - Barcelona
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,880 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2026-10-01 |
What the registry record for NCT06965036 still lists
NCT06965036 is an observational study that tracks outcomes without assigning an intervention. Its 2,880 participants enrollment target places it among the larger protocols in the corpus.
The record links to 2 conditions, with Acute Ischemic Stroke Related to Tandem Occlusion appearing as the primary indexed condition, and to 0 interventions.
NCT06965036 reports a single indexed study location in Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06965036 about?
NCT06965036 is a clinical study titled "Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior and Posterior Circulation". CERES-TANDEM is a multicenter study designed to improve the understanding of "tandem" ischemic stroke -those caused by two blockages in series, one in a neck artery and one in a brain artery-. Because tandem occlusion-related stroke tend to cause more severe brain injury and have been under-represen...
What is the current status of trial NCT06965036?
This trial is currently active not recruiting. The enrollment target is 2,880 participants. The study started on 2018-01-01. Estimated completion is 2026-10-01.
What conditions does trial NCT06965036 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke Related to Tandem Occlusion, Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion.
Who is sponsoring clinical trial NCT06965036?
This trial is sponsored by Azienda Unità Sanitaria Locale della Romagna, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06965036 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI